TS Financial Group (TSFG)’s BioXcel Therapeutics BTAI Stock Holding History

TS Financial Group (TSFG)’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-9	Closed	–	–	748
2024 Q3	$0	Buy	+9	New	+$121	﹤0.01%	779

Other funds holding BTAI

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TS Financial Group (TSFG)'s BTAI Position: Q4 2024 in Review

TS Financial Group (TSFG) sold out of BioXcel Therapeutics (BTAI) in Q4 2024, closing a stake of 9 shares.

TS Financial Group (TSFG) first reported a position in BTAI in Q3 2024 and held it in 1 quarter. The position peaked at $0 in Q3 2024. 49 funds tracked by Wall St. Rank hold BTAI as of Q4 2024.

TS Financial Group (TSFG) reported no remaining BioXcel Therapeutics position as of Q4 2024 after selling out during the quarter.
TS Financial Group (TSFG) sold 9 BioXcel Therapeutics shares in Q4 2024.
TS Financial Group (TSFG) first reported a position in BioXcel Therapeutics in Q3 2024 and held it in 1 quarter.
TS Financial Group (TSFG)'s BioXcel Therapeutics position peaked at $0 in Q3 2024.
49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2024.

Based on TS Financial Group (TSFG)'s 13F filing for Q4 2024, filed 13 Jan 2025.